The EARL FDG-PET/CT Accreditation Programme & Guideline Developments: Results of more than 65 Successfully Accredited Sites and Future Perspectives

Size: px
Start display at page:

Download "The EARL FDG-PET/CT Accreditation Programme & Guideline Developments: Results of more than 65 Successfully Accredited Sites and Future Perspectives"

Transcription

1 The EARL FDG-PET/CT Accreditation Programme & Guideline Developments: Results of more than 65 Successfully Accredited Sites and Future Perspectives

2 Disclosure statement Research support: Philips Healthcare & Roche

3 Biomarkers Biomarkers are physical entities or images of these entities that can be measured and used to indicate a biological process, disease process, or drug response A surrogate endpoint, or marker, is a laboratory measurement or physical sign used in therapeutic trials as a substitute for a clinically meaningful endpoint that is a direct measure of how a patient feels, functions, or survives, and is expected to predict the effect of the therapy Courtesy of Arturo Chiti

4 Molecular Imaging with (Q)PET (with CT and/or MR) Different radiopharmaceuticals to image different metabolic pathways Diagnosis and staging Restaging Biological Characterization Response Evaluation Therapy Courtesy of Arturo Chiti

5 Standardised Uptake Value SUV TBW = ct[ kbq/ ml] Dose[ MBq]/ weight[ kg] SUV is activity concentration ratio Weight is sometimes replaced by BSA, LBM, BMI

6 Use of SUV in response assessment studies Absolute SUV: -Patient eligibility -Patient stratification -Lesion selection (PERCIST) -Residual SUV Relative of % SUV changes -% change of the same lesions (EORTC) -% change of the (5) hottest lesions per scan + SUV=0.9 (PERCIST) For all applications absolute SUV and SUV changes are used

7 Entire chain of process determines quantitative result of an imaging biomaker Picture taken from QIBA FDG PET/CT profile (draft)

8 Basic principle is same for most (PET based) imaging biomarkers (1) (2) (3) (4) Standardisation/harmonization implies: 1. Guidelines or imaging procedures to address user/observer related factors (uptake time, patient preparation, data analysis/intepretation) 2. Requirements for image data acquisition (activity, scan acquisition parameters, reconstruction settings) 3. Rules for image/data analysis 4. Criteria for data (e.g. response) intepretation

9 PET imaging / SUV uncertainties Technical factors Relative calibration between PET scanner and dose calibrator (10%) Residual activity in syringe (5%) Incorrect synchronisation of clocks (10%) Injection vs calibration time (10%) Quality of administration (50%) Physics related factors Scan acquisition parameters (15%) Image reconstruction parameters (30%) Use of contrast agents (15%) ROI (50%) Biological factors Uptake period (15%) Patient motion and breathing (30%) Blood glucose levels (15%) R. Boellaard 2009, J Nucl Med Supplement Issue 50: 11S

10 Glu 200 mg% Glu 79 mg% Karoline Spaepen-Sigrid Stroobants Department of Nuclear Medicine University Hospital Gasthuisberg Leuven, Belgium

11 Lowe VJ et al. Optimum scanning protocol?for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995, image taken from Shankar et al. JNM 2006

12 Effects of different number of OSEM iterations, as seen in the Netherlands, on SUV SUVmax = SUV 50%=

13

14 Entire chain of process determines quantitative result of an imaging biomaker Needs consistency of the execution of imaging procedure in longitudinal setting

15 Standardisation and quantification Personalized management of cancer allows the use of specific drugs Molecular imaging techniques can be used to study several tumors FDG PET-CT has been proposed as a surrogate biomarker for monitoring cancer therapies There are several radiopharmaceuticals other than FDG, with the potential to characterize tumors and monitor response to therapy Imaging biomarkers must be standard and quantitative Courtesy of Arturo Chiti

16 Quantitative imaging biomarker Requirements for (quantitative) imaging biomarkers: Repeatability (in one patient using the same PET/CT system) Reproducibility (between patients, systems and institutions) of performance, analysis and interpretation This implies that standardisation & harmonisation of imaging procedures are essential

17 FDG PET and PET/CT: EANM Procedure Guidelines for Tumour PET Imaging: version 1.0 Eur.J.Nucl.Med.Mol.Imag. 2010

18 The EANM guideline for FDG PET and PET/CT provides recommendations for: Minimising physiological or biological effects by patient preparation guidelines Procedures to ensure accurate FDG administration Matching of PET study statistics ( image quality )by prescribing FDG dosage as function of patient weight, type of scanner, acquisition mode and scan duration Matching of image resolutionby specifying image reconstruction settings and providing activity concentration recovery coefficients specifications (QC experiment) Standardisation of data analysisby prescribing region of interest strategies and SUV measures Multi-center QC/QA procedures for PET and PET/CT scanners

19 Multi-center QC and calibration Daily QC conform standard procedure of system / manufacturer Calibration QC using (cylindrical) phantom (15-30cm diameter) Adjusted NEMA NU Image Quality procedure/measurement to measure recovery coefficients as function of sphere size (= effective image resolution ) CT-QC cf recommendations of ESR/national law Misc. QC (e.g. for scales, alignment etc)

20 Multi-center QC and calibration Calibration QC specification: maximum allowable calibration deviation = + or 10% (global) SUV recovery specifications: for SUVmax (focus as SUVmax is used clinically!) for SUVmean [BQML] SUV recovery coefficient VOI A50%, new limits Sphere volume (ml)

21 Multi-center harmonization of quantification Calibration QC PET/CT and DC Results at first testm Maccredited sites GE Philips Siemens GE Philips Siemens GE Philips Siemens ~5% outside specs Comparable calibration accuracy and SUV recovery among sites and vendors is feasible (n=>65)

22 Multi-center harmonization of quantification Image Quality % SUV recovery [BQML] Results at first testm Maccredited sites SUV Max RC - all vendors 1.6 SUV MAX RC - all vendors SUV MAX RC SUV MAX RC Sphere volume (ml) Sphere volume (ml) Comparable SUV recovery among sites and vendors is feasible (n=>65)

23 Multi-center harmonization of quantification Image Quality % SUV recovery [BQML] SUV MAX SUV MAX RC GE Philips Siemens Sphere volume (ml) Small differences in RC curve shape between vendors

24 Should we use PSF reconstructions? Lasnon et al. EJNMMI 2013 Most accurate PSF + SUVmean (VOI=3D-50%) Most accurate No PSF + SUVmax Note that simple SUVmean & 3D 50% VOIs only perform well: - Simple phantoms - No tracer uptake heterogeneity - Good scan statistics None of these characteristics are met in clinical practice. (Cheebsumon et al. JNM 2011, EJNMMI 2011)

25 Why do we use SUVmax? SUVmax suffers from upward bias due to noise (Boellaard et al, JNM 1996, 2011, Lodge et al, JNM 2011) poor reproducibility and accuracy for PSF (HD) reconstructions (Tong, IEEE TNS 2011, Rahmim et al. MedPhys 2013, Lasnon et al. EJNMMI 2013) Despite these limitions: May represent metabolically most active part of tumor VOIs are not standardized simple isocontour work only well for simple phantoms CT and PET based manual segmentation suffer from observer variability CT based segmentation may suffer from CT-PET alignment issues PET based automated delineation methods: variability of methods variability in implementation of same method performance depend strongly on underlying image characteristics (Cheebsumon et al. JNM2011, EJNMMI 2011) cannot deal well with tracer uptake heterogeneity Therefore, need to optimize image quality for use of SUVmax

26 Future directions SUVmax suffers from: upward bias due to noise (Boellaard et al, JNM 1996, 2011, Lodge et al, JNM 2011, Lasnon EJNMMI 2013) poor reproducibility and accuracy for PSF (HD) reconstruction (Boellaard et al., JNM 2011, Tong, IEEE TNS 2011, Lasnon et al. JNM 2013) 1. Explore use of SUVpeak: 1ml spherical VOI located at highest average value good surrogate for SUVmax almost no observer variability less sensitive to scanner performance differences BUT, no everywhere available inventory among accredited sites is ongoing (Q4/2013) 2. Explore implementation of EARL compliant acq/recon protocols by vendors Positive feedback from and ongoing discussions with GE, Philips and Siemens Explore strategy proposed by Lasnon et al. EJNMMI nd recon or post-recon filter after PSF recon 3. Include measure and upper limit for noise within the IQ-QC experiments

27 Future directions 1.2 SUV MAX Makris et al. EJNMMI SUV PEAK 1 1 SUV MAX RC SUV PEAK RC Sphere volume Sphere volume (ml) SUV RC for 2 different PET/CT systems: more difference in SUV MAX RC between systems than with PEAK SUV PEAK RC more smooth curve, less sensitive to image artefacts (next slide)

28 Some typical image artefacts Edge or ring (Gibbs) artefacts: Allways seen with PSF based reconstructions Frequently on specific TF systems (>50% of cases) Problems in case using SUVmax Mitigation: SUVpeak?

29 Future directions UPICT uniformity of protocols in clinical trials: FDG PET/CT consensus guideline out for public comment (Q4/2013) QIBA FDG PET/CT Profile: under review/revision addresses performance and compliance criteria (systems and users)

30 Multi-center harmonization of quantification Main principles of EANM GL and EARL accreditation Standardisation of PET examinination procedure Quantification is combination of: image resolution image noise data analysis methods (SUVmax de facto the standard in practice) EARL QC s s based on exploration to find highest common denominator in performance of scanner calibration SUV-RCs SUVmax, transition to SUV Peak Scanner performance harmonization is feasible on a large scale, but long term sustainability requires support and service from vendors goal of SNM-CTN & EANM/EARL

31 FDG PET and PET/CT: EANM Procedure Guidelines for Tumour PET Imaging: version 1.0 Ronald Boellaard, Mike O Doherty, Wolfgang A. Weber, Felix M. Mottaghy, Markus N. Lonsdale, Sigrid G. Stroobants, Wim J.G. Oyen, Joerg Kotzerke, Otto S. Hoekstra, Jan Pruim, Paul K. Marsden, Klaus Tatsch, Corneline J. Hoekstra, Eric.P. Visser, Bertjan Arends, Fred J. Verzijlbergen, Josee M. Zijlstra, Emile FI Comans, Adriaan A. Lammertsma, Anne M. Paans, Antoon T. Willemsen, Thomas Beyer, Andreas Bockisch, Cornelia Schaefer-Prokop, Dominique Delbeke, Richard P. Baum, Arturo Chiti, Bernd J. Krause. Eur.J.Nucl.Med.Mol.Imag. 2010

32 Thank you for your attention!

Feasibility of state of the art PET/CT systems performance harmonisation

Feasibility of state of the art PET/CT systems performance harmonisation European Journal of Nuclear Medicine and Molecular Imaging (208) 45:344 36 https://doi.org/0.007/s00259-08-3977-4 ORIGINAL ARTICLE Feasibility of state of the art PET/CT systems performance harmonisation

More information

Ronald Boellaard Terez Sera Andres Kaalep

Ronald Boellaard Terez Sera Andres Kaalep EANM Research Ltd (EARL) New EARL PET/CT Performance Standards for Oncological PET/CT Studies Ronald Boellaard Terez Sera Andres Kaalep EANM Research Ltd (EARL) Joint Symposium - EANM/EARL EANM 18 Düsseldorf:

More information

PET/CT imaging for response monitoring in multicenter studies: An update and future challenges

PET/CT imaging for response monitoring in multicenter studies: An update and future challenges PET/CT imaging for response monitoring in multicenter studies: An update and future challenges Paul Kinahan, PhD Director of PET/CT Physics Imaging Research Laboratory Department of Radiology University

More information

PET in clinical trials

PET in clinical trials PET in clinical trials Tim Turkington, PhD Duke University How might a clinical trial differ from routine clinical PET/CT imaging? IRB Patient Preparation Radiotracer Scan Protocol Image reconstruction

More information

CQIE PET PROCEDURES. American College of Radiology Clinical Research Center. Centers for Quantitative Imaging Excellence LEARNING MODULE

CQIE PET PROCEDURES. American College of Radiology Clinical Research Center. Centers for Quantitative Imaging Excellence LEARNING MODULE Centers for Quantitative Imaging Excellence LEARNING MODULE CQIE PET PROCEDURES American College of Radiology Clinical Research Center Imaging Core Laboratory v2.1 Centers for Quantitative Imaging Excellence

More information

Quantification in emission tomography: challenges, solutions, performance and impact

Quantification in emission tomography: challenges, solutions, performance and impact EuroMedIm 2006 Quantification in emission tomography: challenges, solutions, performance and impact Irène Buvat U678 INSERM, Paris buvat@imed.jussieu.fr http://www.guillemet.org/irene EuroMedIm 2006 -

More information

Jeffrey T. Yap, Ph.D. Dana-Farber Cancer Institute Brigham & Women s Hospital Harvard Medical School

Jeffrey T. Yap, Ph.D. Dana-Farber Cancer Institute Brigham & Women s Hospital Harvard Medical School 1 Case Studies of Imaging Biomarkers - Description and requirements for standardized acquisition in multicenter trials: DCE-MRI, Volumetric CT, FDG-PET/CT Jeffrey T. Yap, Ph.D. Dana-Farber Cancer Institute

More information

Optimisation of Clinical Protocols

Optimisation of Clinical Protocols Optimisation of Clinical Protocols K Pathmaraj MSc, BSc, Grad Dip Comp Science Chief Technologist (PET) Dept of Molecular Imaging & Therapy Austin Health, Victoria, Australia Senior Clinical Associate

More information

Multicenter oncology clinical trials are increasingly using

Multicenter oncology clinical trials are increasingly using Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom John J. Sunderland

More information

QIN: Overview of Scientific Challenges

QIN: Overview of Scientific Challenges QIN: Overview of Scientific Challenges Goal: Robust methods for Imaging (QI) as a Biomarker for Response to Therapy RIDER: Public Resource to promote QI Methods and Standards QIN: Quantitative Imaging

More information

Role of PET/CT Imaging

Role of PET/CT Imaging Quantification of 3-D PET/CT Imaging Role of PET/CT Imaging Janet R. Saffer 1,2, Joshua S. Scheuermann 1,2, Joel S. Karp 1,2, Amy Perkins 3 1. Department of Radiology, University of Pennsylvania 2. PET

More information

Facilitating the Use of Imaging Biomarkers in Therapeutic Clinical Trials. Michael Graham, PhD, MD President, SNM Co-chair, Clinical Trials Network

Facilitating the Use of Imaging Biomarkers in Therapeutic Clinical Trials. Michael Graham, PhD, MD President, SNM Co-chair, Clinical Trials Network Facilitating the Use of Imaging Biomarkers in Therapeutic Clinical Trials Michael Graham, PhD, MD President, SNM Co-chair, Clinical Trials Network Facilitating the Use of Imaging Biomarkers in Therapeutic

More information

From Analysis Method to Quantitative Imaging Biomarker

From Analysis Method to Quantitative Imaging Biomarker From Analysis Method to Quantitative Imaging Biomarker Developments in Healthcare Imaging Connecting with Industry 18 th October 2017 Sarah Lee, PhD, SMIEEE Medical Image Analysis Consultant Disclosures

More information

Progress Towards an International Image Quality Monitoring Framework for Quantitative Imaging

Progress Towards an International Image Quality Monitoring Framework for Quantitative Imaging Progress Towards an International Image Quality Monitoring Framework for Quantitative Imaging Ricardo S. Avila rick.avila@accumetra.com October 2, 2017 Quantitative Imaging Workshop XIV Hubble Space Telescope

More information

Introduction to Quantitative Imaging as a Biomarker in Clinical Trials

Introduction to Quantitative Imaging as a Biomarker in Clinical Trials Quantitative Medical Imaging for Clinical Research and Practice Educational Session ACRIN 2009 Introduction to Quantitative Imaging as a Biomarker in Clinical Trials Katarzyna J. Macura, MD, PhD Johns

More information

Automatic Descending Aorta Segmentation in Whole-Body PET-CT Studies for PERCIST-based Thresholding

Automatic Descending Aorta Segmentation in Whole-Body PET-CT Studies for PERCIST-based Thresholding Automatic Descending Aorta Segmentation in Whole-Body PET-CT Studies for PERCIST-based Thresholding Lei Bi, Jinman Kim, Member, IEEE, Lingfeng Wen, Member, IEEE and David Dagan Feng, Fellow, IEEE Abstract

More information

AAPM Scientific Meeting Imaging Symposium. State of the Art in Quantitative Imaging CT, PET and MRI. Which Imaging Modality is the Most Quantitative

AAPM Scientific Meeting Imaging Symposium. State of the Art in Quantitative Imaging CT, PET and MRI. Which Imaging Modality is the Most Quantitative AAPM Scientific Meeting Imaging Symposium State of the Art in Quantitative Imaging CT, PET and MRI Michael McNitt-Gray, PhD, FAAPM; UCLA Paul Kinahan, PhD, U. Washington Ed Jackson, PhD, FAAPM, UT-MD Anderson

More information

Regulatory issues in PET drug development and standardization of PET imaging

Regulatory issues in PET drug development and standardization of PET imaging NSFC/CAS/JSPS International Workshop Frontier of Translational Medicine: Molecular Imaging Dec 6, 2014 Regulatory issues in PET drug development and standardization of PET imaging Michio Senda, MD PhD

More information

New PET/CT from Siemens helps more patients benefit from premium technologies

New PET/CT from Siemens helps more patients benefit from premium technologies Press Healthcare Erlangen, October 9, 2015 EANM 2015, Congress Center Hamburg (CCH) New PET/CT from Siemens helps more patients benefit from premium technologies Versatile new PET/CT system addresses a

More information

University of Groningen

University of Groningen University of Groningen Guidelines for quality control of PET/CT scans in a multicenter clinical study Hristova, Ivalina; Boellaard, Ronald; Galette, Paul; Shankar, Lalitha K.; Liu, Yan; Stroobants, Sigrid;

More information

How to organize a Clinical Theranostics Trial?

How to organize a Clinical Theranostics Trial? How to organize a Clinical Theranostics Trial? International Course on THERANOSTICS AND MOLECULAR RADIOTHERAPY Julie Gaye IJB-CTSU October 4, 2017 Research proposal Competent Authorities and/or Ethics

More information

UPICT template structure as modified by QIBA VolCT Technical Committee June 25, 2009

UPICT template structure as modified by QIBA VolCT Technical Committee June 25, 2009 UPICT template structure as modified by QIBA VolCT Technical Committee June 25, 2009 The QIBA VolCT Technical Committee modified and used the UPICT template for a VolCT profile on CT Lung Nodule Volume

More information

CQIE MRI PROCEDURES. American College of Radiology Clinical Research Center. Centers for Quantitative Imaging Excellence LEARNING MODULE

CQIE MRI PROCEDURES. American College of Radiology Clinical Research Center. Centers for Quantitative Imaging Excellence LEARNING MODULE Centers for Quantitative Imaging Excellence LEARNING MODULE CQIE MRI PROCEDURES American College of Radiology Clinical Research Center Imaging Core Laboratory v.2 Centers for Quantitative Imaging Excellence

More information

Alternative Career Opportunities for Medical Physicists

Alternative Career Opportunities for Medical Physicists Alternative Career Opportunities for Medical Physicists Robert Jeraj Professor of Medical Physics, Human Oncology, Radiology and Biomedical Engineering Director of Translational Imaging Research Program

More information

Title Clinical Contribution of PET/CT in Perspective of a Radiologist. Author(s) Nakamoto, Yuji Citation Clinical lymphoma, myeloma & leukem Issue Date 2014-02 URL http://hdl.handle.net/2433/182042 Right

More information

Mirada Case Study. VentureFest, July

Mirada Case Study. VentureFest, July Mirada Case Study VentureFest, July 2015 Synopsis of Mirada Medical Founded in 1999 as a spin-out from the University of Oxford University had 10% equity Headquartered at the OCFI, Oxford Mirada USA based

More information

The time has come. Philips GEMINI TF PET/CT with TruFlight technology

The time has come. Philips GEMINI TF PET/CT with TruFlight technology The time has come Philips GEMINI TF PET/CT with TruFlight technology TruFlight has arrived Time-of-flight technology has always held the promise of better PET imaging. But it took Philips to harness its

More information

Biophysical Considerations in the Precision of Quantitative 18 F-FDG PET/CT DISSERTATION

Biophysical Considerations in the Precision of Quantitative 18 F-FDG PET/CT DISSERTATION Biophysical Considerations in the Precision of Quantitative 18 F-FDG PET/CT DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School

More information

Precision in Quantitative Imaging: Trial Development and Quality Assurance

Precision in Quantitative Imaging: Trial Development and Quality Assurance Precision in Quantitative Imaging: Trial Development and Quality Assurance Susanna I Lee MD, PhD Thanks to: Mitchell Schnall, Mark Rosen. Dan Sullivan, Patrick Bossuyt Imaging Chain: Patient Data Raw data

More information

DCE MRI Team Activity. Gudrun Zahlmann, Edward Jackson, Sandeep Gupta

DCE MRI Team Activity. Gudrun Zahlmann, Edward Jackson, Sandeep Gupta DCE MRI Team Activity Gudrun Zahlmann, Edward Jackson, Sandeep Gupta QIBA Groundwork DCE-MRI Technical Characteristics and Standards Groundwork ( precursor questions ) Diagnostic Accuracy and Reproducibility

More information

GE Healthcare. Introducing Discovery MI DISCOVERY MI

GE Healthcare. Introducing Discovery MI DISCOVERY MI GE Healthcare Introducing Discovery MI DISCOVERY MI Introducing Discovery MI Introducing Discovery MI MEANINGFUL INSIGHTS. FROM YOUR PATIENT TO EVERY PATIENT. Meet Discovery TM MI. A PET/CT system conceptualized

More information

Lead the way. Molecular Imaging. GE Healthcare. imagination at work

Lead the way. Molecular Imaging. GE Healthcare. imagination at work 2010 General Electric Company All rights reserved. General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time

More information

QIBA Working Session

QIBA Working Session QIBA Working Session Wednesday, November 30, 2011 November 30, 2011 QIBA Session Plenary Session Agenda 3:00 PM Year in Review: Status of the Profiles Sullivan Schwartz; Zahlmann; Kinahan QIBA visits to

More information

NIST Medical Imaging Informatics Activities. Medical Imaging

NIST Medical Imaging Informatics Activities. Medical Imaging NIST Medical Imaging Informatics Activities Ram Sriram Mary Brady Alden Dima Medical Imaging Biomarker Testing Improving Change Analysis in Lung Cancer Statistically Valid and Clinically Meaningful Biomarkers

More information

8/1/2016 TOTAL-BODY METABOLIC IMAGING. Whole-Body PET/CT. Acknowledgements

8/1/2016 TOTAL-BODY METABOLIC IMAGING. Whole-Body PET/CT. Acknowledgements TOTAL-BODY METABOLIC IMAGING Simon Cherry Ramsey Badawi Jinyi Qi Terry Jones Departments of Radiology and Biomedical Engineering University of California, Davis Acknowledgements Funding: UC Davis Research

More information

Advanced molecular imaging. Proven accuracy inspires confidence. Philips Vereos Digital PET/CT

Advanced molecular imaging. Proven accuracy inspires confidence. Philips Vereos Digital PET/CT Advanced molecular imaging Proven accuracy inspires confidence Philips Vereos Digital PET/CT At Philips we believe that there is always a way to make life better. In healthcare, that means breaking down

More information

HHSN C Quantitative Imaging Biomarkers Alliance (QIBA)

HHSN C Quantitative Imaging Biomarkers Alliance (QIBA) HHSN268201300071C Quantitative Imaging Biomarkers Alliance (QIBA) PROGRESS REPORT: AS OF MARCH 2014 This progress report is stated in terms given in the accepted Work Plan. This progress report is organized

More information

COCIR CT Manufacturers Voluntary Commitment Regarding CT Dose 2014 Annual Report

COCIR CT Manufacturers Voluntary Commitment Regarding CT Dose 2014 Annual Report Preamble COCIR CT Manufacturers Voluntary Commitment Regarding CT Dose 2014 Annual Report This 2 nd Annual Report defines the COCIR CT manufacturers voluntary commitment to HERCA as a result of the meeting

More information

Part 3 Oral Exam Content Guide

Part 3 Oral Exam Content Guide Initial Certification in Medical Physics Part 3 Oral Exam Content Guide The oral examination is designed to test your knowledge and fitness to practice applied medical physics in the specified specialty(ies).

More information

QIBA Profile: Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening

QIBA Profile: Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening QIBA Profile: Small Lung Nodule Assessment in CT Screening Profile - 2017 1 2 3 4 5 6 QIBA Profile: Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening 7 8 Stage: Publicly Reviewed

More information

RSNA/ACRIN Imaging Researchers Workshop Session II Informatics Tools in Support of Clinical and Translational Research

RSNA/ACRIN Imaging Researchers Workshop Session II Informatics Tools in Support of Clinical and Translational Research RSNA/ACRIN Imaging Researchers Workshop Session II Informatics Tools in Support of Clinical and Translational Research Moderator Michael V. Knopp, MD. Ph.D. Professor of Radiology and Novartis Chair of

More information

PETMETPAT: HARMONISATION METABOLIC FDG BRAIN PATTERN CHARACTERISTICS

PETMETPAT: HARMONISATION METABOLIC FDG BRAIN PATTERN CHARACTERISTICS PETMETPAT: HARMONISATION METABOLIC FDG BRAIN PATTERN CHARACTERISTICS Report of a JPND Working Group on Harmonisation and Alignment in Brain Imaging Methods April 2018 Report of JPND project PETMETPAT (Leenders

More information

QIBA Profile: Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening

QIBA Profile: Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening QIBA Profile: Lung Nodule Assessment in CT Screening Profile - 2017 1 2 3 4 5 6 QIBA Profile: Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening 7 8 Stage: Publicly Reviewed (draft)

More information

Quantitative Imaging Biomarker DCE - MRI

Quantitative Imaging Biomarker DCE - MRI Quantitative Imaging Biomarker DCE - MRI DCE MRI: What is it about? DCE MRI: quantitative analysis of dynamic T1 contrast enhanced images Use cases: Clinical trial related UC1: pharmacodynamic investigations

More information

GE Healthcare. PET/CT + MR Trimodality Imaging

GE Healthcare. PET/CT + MR Trimodality Imaging Unlocking new possibilities with PET/CT + MR 1 PET/CT MR PET/CT + MR The exquisite soft-tissue-contrast of 3.0T MR. The exceptional metabolic insight of PET imaging. The precise anatomical reference of

More information

Advantages and challenges of whole-body MR-PET. Gaspar Delso Axel Martinez-Möller Stephan Nekolla Sibylle Ziegler

Advantages and challenges of whole-body MR-PET. Gaspar Delso Axel Martinez-Möller Stephan Nekolla Sibylle Ziegler Advantages and challenges of whole-body MR-PET Gaspar Delso Axel Martinez-Möller Stephan Nekolla Sibylle Ziegler Why MR+PET? MR High spatial resolution (~1mm) Good imaging of anatomy. Excellent soft-tissue

More information

Accuracy, Precision and Measurement Validation

Accuracy, Precision and Measurement Validation Accuracy, Precision and Measurement Validation Ángel Alberich-Bayarri, PhD 1 Biomedical Imaging Research Group GIBI230 La Fe Health Research Institute 2 QUIBIM Quantitative Imaging Biomarkers in Medicine

More information

RESEARCH 4 LIFE. EARL at a glance: Proving the Quality of Nuclear Medicine. EANM. (Version October 2013)

RESEARCH 4 LIFE. EARL at a glance: Proving the Quality of Nuclear Medicine.  EANM. (Version October 2013) RESEARCH 4 LIFE an EANM European Association of Nuclear Medicine initiative EARL at a glance: Proving the Quality of Nuclear Medicine (Version October 2013) http://earl.eanm.org 1 European Association

More information

Calibration Test of PET Scanners in a Multi-Centre Clinical Trial on Breast Cancer Therapy Monitoring Using 18F-FLT

Calibration Test of PET Scanners in a Multi-Centre Clinical Trial on Breast Cancer Therapy Monitoring Using 18F-FLT Calibration Test of PET Scanners in a Multi-Centre Clinical Trial on Breast Cancer Therapy Monitoring Using 18F-FLT Francis Bouchet 1 *, Lilli Geworski 2, Bernd O. Knoop 2, Ludovic Ferrer 3, Alina Barriolo-Riedinger

More information

2009 Strategic Planning Meeting SNM Clinical Trials Network Chicago, IL

2009 Strategic Planning Meeting SNM Clinical Trials Network Chicago, IL 2009 Strategic Planning Meeting SNM Clinical Trials Network Chicago, IL Wednesday, September 30, 2009 AGENDA Item BREAKFAST Welcome and Introductions Time 8:00am 8:15 Discussion Leaders M. Graham 2009

More information

COCIR CT MANUFACTURERS VOLUNTARY COMMITMENT REGARDING CT DOSE OPTIMIZATION Annual Report

COCIR CT MANUFACTURERS VOLUNTARY COMMITMENT REGARDING CT DOSE OPTIMIZATION Annual Report COCIR CT MANUFACTURERS VOLUNTARY COMMITMENT REGARDING CT DOSE OPTIMIZATION 2015 Annual Report Preamble In 2010 discussions took place between COCIR and the Heads of European Radiation Competent Authorities

More information

Impact of MR-safe headphones on PET attenuation in combined PET/MRI scans

Impact of MR-safe headphones on PET attenuation in combined PET/MRI scans Büther et al. EJNMMI Research (2016) 6:20 DOI 10.1186/s13550-016-0178-7 SHORT COMMUNICATION Open Access Impact of MR-safe headphones on PET attenuation in combined PET/MRI scans Florian Büther 1*, Alexis

More information

PET/MR: A COMMERCIAL SUCCESS STORY?

PET/MR: A COMMERCIAL SUCCESS STORY? PET/MR: A COMMERCIAL SUCCESS STORY? ANTONIS KALEMIS P H D M B A Philips Healthcare Snr Manager, Clinical Science - Advanced Molecular Imaging AIPES (Association of Imaging Producers & Equipment Suppliers)

More information

Deep Learned and Practical

Deep Learned and Practical Deep Learned and Practical Implementing Machine Learning Techniques in the Real World Timor Kadir DPhil Mirada Medical CTO Optellum CTO Visiting Fellow University of Oxford 7/31/2017 1 Disclosures Mirada

More information

WHY QIBA: MR SPECIFICS

WHY QIBA: MR SPECIFICS Quantitative Imaging Biomarker Alliance PRINCIPAL LOGISTICAL AND FINANCIAL SUPPORT PROVIDED BY RSNA WHY QIBA: MR SPECIFICS Corporation Visit Autumn 2010 Andrew J. Buckler, MS Program Director, QIBA Our

More information

Biograph TruePoint PET CT. The World s First HD PET Platform.

Biograph TruePoint PET CT. The World s First HD PET Platform. Biograph TruePoint PET CT The World s First HD PET Platform www.siemens.com/mi Biograph TruePoint PET CT A flexible, high-powered medical imaging platform, Siemens Biograph offers an unmatched range of

More information

2017 ACR Computed Tomography Quality Control Manual FAQS

2017 ACR Computed Tomography Quality Control Manual FAQS Updated 11-15-2017 2017 ACR Computed Tomography Quality Control Manual FAQS Q. The updated 2017 ACR Computed Tomography Quality Control Manual has been released. (Visit www.acr.org/education/education-catalog.)

More information

Outline. Davis et al., Clinical Cancer Research. Surrogate markers. Defining outcomes. Issues relating to measurement

Outline. Davis et al., Clinical Cancer Research. Surrogate markers. Defining outcomes. Issues relating to measurement Outline Davis et al., Clinical Cancer Research Surrogate markers Defining outcomes Issues relating to measurement Motivating Example: PD Analysis of Effects of SU5416 or SU6668 Clinical outcomes of interest

More information

Review Article Dosage optimization in positron emission tomography: state-of-the-art methods and future prospects

Review Article Dosage optimization in positron emission tomography: state-of-the-art methods and future prospects Am J Nucl Med Mol Imaging 2015;5(5):527-547 www.ajnmmi.us /ISSN:2160-8407/ajnmmi0014068 Review Article Dosage optimization in positron emission tomography: state-of-the-art methods and future prospects

More information

Nuclear Medicine Solutions

Nuclear Medicine Solutions Nuclear Medicine Solutions Bringing your vision to life The field of nuclear medicine offers exciting emerging opportunities to improve patient care and can no longer be overlooked in diagnostics. A welldesigned,

More information

Multi-site quality and variability analysis of 3D FDG PET segmentations based on phantom and clinical image data

Multi-site quality and variability analysis of 3D FDG PET segmentations based on phantom and clinical image data Multi-site quality and variability analysis of 3D FDG PET segmentations based on phantom and clinical image data Reinhard R. Beichel a) Department of Electrical and Computer Engineering, The University

More information

Imaging Requirements (RTOG 1106/ACRIN 6697) Adam Opanowski, CNMT, PET, NCT, R.T.(N)(ARRT) Imaging Analyst ACR Core Laboratory

Imaging Requirements (RTOG 1106/ACRIN 6697) Adam Opanowski, CNMT, PET, NCT, R.T.(N)(ARRT) Imaging Analyst ACR Core Laboratory Imaging Requirements (RTOG 1106/ACRIN 6697) Adam Opanowski, CNMT, PET, NCT, R.T.(N)(ARRT) Imaging Analyst ACR Core Laboratory Imaging Qualification and Quality Control Patients must be scanned on PET/CT

More information

Methods in Clinical Cancer Research Workshop Format for Protocol Concept Synopsis Sheet (blank) SYNOPSIS

Methods in Clinical Cancer Research Workshop Format for Protocol Concept Synopsis Sheet (blank) SYNOPSIS B Methods in Clinical Cancer Research Workshop Format for Protocol Concept Synopsis Sheet (blank) elow is the format to follow for the concept sheet for protocols. It is based on the International Committee

More information

Infrastructure to Integrate Imaging in Clinical Trials

Infrastructure to Integrate Imaging in Clinical Trials AAPM Joint Imaging/Therapy Symposium Imaging as a Biomarker Infrastructure to Integrate Imaging in Clinical Trials Financial Disclosures/COI Scientific Advisory Board, MDS Nordion Daniel C. Sullivan, M.D.

More information

Quality Assurance for particle beam therapy

Quality Assurance for particle beam therapy Quality Assurance for particle beam therapy PTCOG Educational Workshop, Essen 2013 Heidelberg Ion Beam Therapy Center at the University Hospital German Cancer Research Center, Heidelberg, Germany Outline

More information

GE Healthcare. Optima NM/CT 640

GE Healthcare. Optima NM/CT 640 GE Healthcare Optima NM/CT 640 Great and lasting performance in a SPECT/CT system? Precisely. We invented hybrid SPECT/CT. And now we re perfecting it. Introducing the Optima* NM/CT 640 from GE Healthcare

More information

Molecular Imaging. Professor Sir Michael Brady FRS FREng Department of Engineering Science Oxford University

Molecular Imaging. Professor Sir Michael Brady FRS FREng Department of Engineering Science Oxford University Molecular Imaging Professor Sir Michael Brady FRS FREng Department of Engineering Science Oxford University Over the past 20 years, we have developed new ways to image anatomy, new ways to see inside the

More information

The EORTC Molecular Screening programme SPECTA

The EORTC Molecular Screening programme SPECTA The EORTC Molecular Screening programme SPECTA February 2016 Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium The changing shape of clinical research Phase I RESOURCES Phase III The changing

More information

Magnetic Resonance Spectroscopy from fundamental developments to improved noninvasive diagnosis and characterisation of children s brain tumours.

Magnetic Resonance Spectroscopy from fundamental developments to improved noninvasive diagnosis and characterisation of children s brain tumours. Magnetic Resonance Spectroscopy from fundamental developments to improved noninvasive diagnosis and characterisation of children s brain tumours. Martin Wilson IOP Medical Physics Group Scientific and

More information

Overview of IMV Data: Perspectives on Large Scale Data Collection. December 8, 2011

Overview of IMV Data: Perspectives on Large Scale Data Collection. December 8, 2011 Overview of IMV Data: Perspectives on Large Scale Data Collection December 8, 2011 Background IMV is a market research and database provider specializing in medical markets; including diagnostic imaging,

More information

siemens.com/mct-flow Biograph mct Flow Moving the standard to personalized care.

siemens.com/mct-flow Biograph mct Flow Moving the standard to personalized care. siemens.com/mct-flow Biograph mct Flow Moving the standard to personalized care. Every patient is unique. Every organ is different. Every disease is specific. So a one-size-fits-all exam protocol is not

More information

Philips PET/CT Gemini GXL. Total performance. Total confidence.

Philips PET/CT Gemini GXL. Total performance. Total confidence. Philips PET/CT Gemini GXL Total performance. Total confidence. Gemini GXL The one for all. Healthcare isn t about to slow down. Your best bet? 2 Accelerate. All patients. All applications. All the time.

More information

An automatic delineation method for bone marrow absorbed dose estimation in

An automatic delineation method for bone marrow absorbed dose estimation in Makris et al. EJNMMI Physics (2016) 3:13 DOI 10.1186/s40658-016-0149-0 EJNMMI Physics ORIGINAL RESEARCH Open Access An automatic delineation method for bone marrow absorbed dose estimation in 89 Zr PET/CT

More information

Quantitative Techniques in PET-CT Imaging

Quantitative Techniques in PET-CT Imaging 216 Current Medical Imaging Reviews, 2011, 7, 216-233 Quantitative Techniques in PET-CT Imaging Sandip Basu 1, Habib Zaidi 2,3,4, Søren Holm 5 and Abass Alavi 6, * 1 Radiation Medicine Centre (BARC), Tata

More information

Global Siemens Headquarters Siemens AG Wittelsbacherplatz Muenchen Germany

Global Siemens Headquarters Siemens AG Wittelsbacherplatz Muenchen Germany Global Siemens Headquarters Siemens AG Wittelsbacherplatz 2 80333 Muenchen Germany Global Siemens Healthcare Headquarters Siemens AG Healthcare Sector Henkestr. 127 91052 Erlangen Germany Telephone: +49

More information

Guidance for the Physics Aspects of Clinical Trials

Guidance for the Physics Aspects of Clinical Trials AAPM REPORT NO. 113 Guidance for the Physics Aspects of Clinical Trials The Report of AAPM Task Group 113 January 2018 DISCLAIMER: This publication is based on sources and information believed to be reliable,

More information

The Efficiency of Respiratory-gated 18 F-FDG PET/CT in Lung Adenocarcinoma: Amplitude-gating Versus Phase-gating Methods

The Efficiency of Respiratory-gated 18 F-FDG PET/CT in Lung Adenocarcinoma: Amplitude-gating Versus Phase-gating Methods The Efficiency of Respiratory-gated 18 F-FDG PET/CT in Lung Adenocarcinoma: Amplitude-gating Versus Phase-gating Methods Yoshiyuki Kitamura 1, Shingo Baba 1*, Takuro Isoda 1, Yasuhiro Maruoka 1, Satoshi

More information

Quantitative comparison of PET performance Siemens Biograph mct and mmr

Quantitative comparison of PET performance Siemens Biograph mct and mmr Karlberg et al. EJNMMI Physics (2016) 3:5 DOI 10.1186/s40658-016-0142-7 ORIGINAL RESEARCH Open Access Quantitative comparison of PET performance Siemens Biograph mct and mmr Anna M. Karlberg 1*, Oddbjørn

More information

Imaging. Steve Rusckowski CEO Philips Healthcare

Imaging. Steve Rusckowski CEO Philips Healthcare Imaging Steve Rusckowski CEO Philips Healthcare Imaging markets by region and modality 2008 Market by Region 2008, Total Market 14.900 M Market by Modality 2008 LATAM China MCR APAC MCR EMEA Japan Western

More information

SRA: potential in Turku

SRA: potential in Turku Working for health, added lifetime and social welfare Turku University Hospital SRA: potential in Turku Mika Teräs Chief Physicist, Turku University Hospital Professor, Medical Physics, University of Turku

More information

Novel nuclear medicine to advance patient care

Novel nuclear medicine to advance patient care Novel nuclear medicine to advance patient care Addressing Societal Challenges Through Advancing the Medical, Industrial and Research Applications of Nuclear and Radiation Technology Stefano Buono Advisor

More information

Multi-site Quality and Variability Analysis of 3D FDG PET Segmentations based on Phantom and Clinical Image Data

Multi-site Quality and Variability Analysis of 3D FDG PET Segmentations based on Phantom and Clinical Image Data Multi-site Quality and Variability Analysis of 3D FDG PET Segmentations based on Phantom and Clinical Image Data Accepted Article Reinhard R. Beichel, 1, 2, a) Brian J. Smith, 3 Christian Bauer, 1 Ethan

More information

FDA Regulation of Companion Diagnostics

FDA Regulation of Companion Diagnostics FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate

More information

BIOMARKER DISCOVERY IN LOCALLY ADVANCED CERVICAL CANCER: IQ-EMBRACE PETRA VAN HOUDT, JESPER KALLEHAUGE, UULKE VAN DER HEIDE, KARI TANDERUP MARCH 23,

BIOMARKER DISCOVERY IN LOCALLY ADVANCED CERVICAL CANCER: IQ-EMBRACE PETRA VAN HOUDT, JESPER KALLEHAUGE, UULKE VAN DER HEIDE, KARI TANDERUP MARCH 23, BIOMARKER DISCOVERY IN LOCALLY ADVANCED CERVICAL CANCER: IQ-EMBRACE PETRA VAN HOUDT, JESPER KALLEHAUGE, UULKE VAN DER HEIDE, KARI TANDERUP MARCH 23, 2018 Non-responder Responder DCE-MRI FOR PREDICTION

More information

Determination of Dose to Individual Patients in Radionuclide Imaging Procedures including Planar, SPECT and PET. Estimation of dose and not dosimetry

Determination of Dose to Individual Patients in Radionuclide Imaging Procedures including Planar, SPECT and PET. Estimation of dose and not dosimetry Determination of Dose to Individual Patients in Radionuclide Imaging Procedures including Planar, SPECT and PET Lawrence E. Williams, PhD City of Hope National Medical Center Duarte CA 91010 lwilliams@coh.org

More information

WHY QIBA: CT SPECIFICS

WHY QIBA: CT SPECIFICS Quantitative Imaging Biomarker Alliance PRINCIPAL LOGISTICAL AND FINANCIAL SUPPORT PROVIDED BY RSNA WHY QIBA: CT SPECIFICS Corporation Visit Autumn 2010 Andrew J. Buckler, MS Program Director, QIBA Our

More information

RSNA RCA22 Quantitative Imaging: Structured Reporting in 3D Slicer and beyond

RSNA RCA22 Quantitative Imaging: Structured Reporting in 3D Slicer and beyond RSNA 2015 - RCA22 Quantitative Imaging: Structured Reporting in 3D Slicer and beyond Andrey Fedorov, PhD November 29, 2015 Brigham and Women s Hospital / Harvard Medical School Boston, MA, USA fedorov@bwh.harvard.edu

More information

FDA from a Former FDAer: Secrets and insights into regulatory review and drug development

FDA from a Former FDAer: Secrets and insights into regulatory review and drug development FDA from a Former FDAer: Secrets and insights into regulatory review and drug development Andrew E. Mulberg, MD, FAAP Vice-President, Global Regulatory Affairs; Former Division Deputy, DGIEP, U.S. FDA

More information

Discovery NM630 Innovation to expand your care.

Discovery NM630 Innovation to expand your care. GE Healthcare Discovery NM630 Innovation to expand your care. Focus on what matters most. Your reason for being is the health of countless patients who come to you for care. This is why GE Healthcare strives

More information

Low-dose and High-resolution Cardiovascular Imaging with Revolution* CT

Low-dose and High-resolution Cardiovascular Imaging with Revolution* CT GE Healthcare Case study Low-dose and High-resolution Cardiovascular Imaging with Revolution* CT Jean-Louis Sablayrolles, M.D. Laurent Macron, M.D. Jacques Feignoux, M.D. Centre Cardiologique du Nord,

More information

Instructions and Checklist for the Preparation of Data for the Pediatric Administered Activity Survey

Instructions and Checklist for the Preparation of Data for the Pediatric Administered Activity Survey Instructions and Checklist for the Preparation of Data for the Pediatric Administered Activity Survey Thank you for agreeing to participate in the Pediatric Administered Activity Survey of the Nuclear

More information

Computed tomography. High. performance. no trade-offs. Philips Ingenuity CT family

Computed tomography. High. performance. no trade-offs. Philips Ingenuity CT family Computed tomography High performance no trade-offs Philips Ingenuity CT family Keeping you ahead Until now, CT scanning has too often been about trade-offs. You ve been forced to choose between high image

More information

FDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.

FDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D. Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food

More information

Group sequential designs for diagnostic accuracy studies

Group sequential designs for diagnostic accuracy studies Group sequential designs for diagnostic accuracy studies Oke Gerke, Mie H Vilstrup, Ulrich Halekoh, Malene G Hildebrandt, PF Høilund Carlsen Workshop on flexible designs for diagnostic studies, UMC Göttingen,

More information

Clinical Trial Design, Approval Process and Trial Conduct

Clinical Trial Design, Approval Process and Trial Conduct Clinical Trial Design, Approval Process and Trial Conduct Topic: Special Considerations in Gene Transfer: Surrogate Endpoints Michael Kalos, Ph.D. University of Pennsylvania School of Medicine May 18,

More information

/06/$ IEEE. 2653

/06/$ IEEE. 2653 IEEE Nuclear Science Symposium Conference Record M-57 Comparison between the ROI based and pixel based analysis for neuroreceptor studies performed on the high resolution research tomograph (HRRT) Vesna

More information

To improve human health by advancing nuclear medicine, molecular imaging, and radionuclide therapy.

To improve human health by advancing nuclear medicine, molecular imaging, and radionuclide therapy. 1954 2014 CELEBRATING 60 YEARS Strategic Plan Approved September 2013 SNMMI s Timeless Core Ideology Core Ideology describes an organization s consistent identity that transcends all changes related to

More information

Symbia SPECT. Working For You.

Symbia SPECT. Working For You. Symbia SPECT Working For You www.siemens.com/medical Work with confidence. What does it mean to work with confidence? It s clarity not only image clarity but the clarity of mind you can obtain from viewing

More information

Generating ROI with Advanced PET and Diagnostic CT Imaging

Generating ROI with Advanced PET and Diagnostic CT Imaging USTOMER SPOTLIGHT NERR IMGING GROUP PET/T U S T O M E R S P O T L I G H T Generating ROI with dvanced PET and iagnostic T Imaging Known as the ush apital, anberra is ustralia s largest inland city located

More information

Infections & Inflammation Molecular Imaging in Pharmaceutical Research

Infections & Inflammation Molecular Imaging in Pharmaceutical Research Infections & Inflammation Molecular Imaging in Pharmaceutical Research 1 st Faculty of Medicine, Charles University in Prague Drug Development Process William JK et al., Nature Reviews 2008:7; 591-607

More information